ArticleJournal of the American Heart Association2025
Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLonger-term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level. We aimed to investigate the nonfatal longer-term post-SM outcomes from a national all-payer individual-level claims.
methodsThe Symphony Health Claims database (2016-2021) was analyzed to identify all adult patients with obstructive hypertrophic cardiomyopathy who underwent SM in the United States and had at least 1 claim within 120 days before SM. The primary outcome was cardiovascular hospitalizations (CVH) starting >30 days post-SM.
resultsA total of 5324 patient (median age 62.0 [52.0-70.0], 53.2% female, 70% commercial insurance) underwent SM and 95.8% were followed >30 days post SM. During 2.7 (1.2-4.2) years median follow-up, CVH occurred in 46.7% (80% of CVH within 16 months of SM). CVH for new atrial fibrillation/flutter was 25.4%, ventricular arrhythmias 9.7%, syncope 9.3%, myocardial infarction 5.2%, cardiac arrest 1.6%, ventricular septal defect 0.9%, and need for advanced heart failure therapy 0.6%. Repeat SM was required in 43 patients (0.8%). The strongest predictors of CVH post SM were presence of an implantable cardioverter-defibrillator at baseline (adjusted odds ratio [aOR], 1.72 [95% CI, 1.50-1.97],
conclusionsOver a 3-year period, SM for obstructive hypertrophic cardiomyopathy was associated with a high burden of CVH. Investigating the drivers of these events and strategies to mitigate the high incidence of intermediate and long-term nonfatal complications post SM will help improve the care of patients with obstructive hypertrophic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.